152 related articles for article (PubMed ID: 26137283)
1. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma.
Oyama K; Koda M; Sugihara T; Kishina M; Miyoshi K; Okamoto T; Hodotsuka M; Fujise Y; Matono T; Tokunaga S; Okamoto K; Hosho K; Okano J; Murawaki Y
Mol Clin Oncol; 2015 May; 3(3):655-662. PubMed ID: 26137283
[TBL] [Abstract][Full Text] [Related]
2. The Early Decline of α-Fetoprotein and Des-γ-Carboxy Prothrombin Predicts the Response of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma Patients.
Yamamoto S; Onishi H; Takaki A; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Shiraha H; Okada H
Gastrointest Tumors; 2020 Jul; 7(3):83-92. PubMed ID: 32903927
[TBL] [Abstract][Full Text] [Related]
3. Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma.
Hatanaka T; Kakizaki S; Shimada Y; Takizawa D; Katakai K; Yamazaki Y; Sato K; Kusano M; Yamada M
Intern Med; 2016; 55(16):2163-71. PubMed ID: 27522991
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Park WH; Shim JH; Han SB; Won HJ; Shin YM; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2012 Jul; 23(7):927-36. PubMed ID: 22633621
[TBL] [Abstract][Full Text] [Related]
7. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Kuzuya T; Asahina Y; Tsuchiya K; Tanaka K; Suzuki Y; Hoshioka T; Tamaki S; Kato T; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Izumi N
Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
9. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review.
Li C; Zhang Z; Zhang P; Liu J
Hepatol Res; 2014 Oct; 44(10):E11-25. PubMed ID: 23834468
[TBL] [Abstract][Full Text] [Related]
11. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
[TBL] [Abstract][Full Text] [Related]
12. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
13. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
14. Studies on the correlation among the fucosylation index, concentration of alpha-fetoprotein and des-gamma-carboxy prothrombin as prognostic indicators in hepatocellular carcinoma.
Igarashi H; Aoyagi Y; Suda T; Mita Y; Kawai K
Hepatol Res; 2003 Dec; 27(4):280-288. PubMed ID: 14662116
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
16. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
17. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.
Wang CS; Lin CL; Lee HC; Chen KY; Chiang MF; Chen HS; Lin TJ; Liao LY
World J Gastroenterol; 2005 Oct; 11(39):6115-9. PubMed ID: 16273636
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin and alpha-fetoprotein levels as biomarkers for hepatocellular carcinoma and their correlation with radiological characteristics.
Qadeer MA; Abbas Z; Amjad S; Shahid B; Altaf A; Siyal M
World J Gastrointest Pathophysiol; 2024 Apr; 15(1):90893. PubMed ID: 38682024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]